<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="2741d8fd-51c2-46be-880b-99f2b20a6137" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-2a077df2-a26f-4830-90e7-637223c3a356" mediaType="text/x-hl7-title+xml">PROTOPAM Chloride (pralidoxime chloride)
        for Injection<br />R<sub>x</sub> only</title>
<effectiveTime value="20060511" />
<setId root="2741d8fd-51c2-46be-880b-99f2b20a6137" />
<versionNumber value="2" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Baxter Healthcare Corporation</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="C49E35EB-6605-2743-65AD-00C176DF05C5" />
<effectiveTime value="20060511" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="60977-141" codeSystem="2.16.840.1.113883.6.69" />
<name>Protopam Chloride</name>
<formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION" />
<activeIngredient>
<quantity>
<numerator unit="g" value="1">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="1" />
</numerator>
<denominator unit="mL" value="20">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="20" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="38X7XS076H" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>pralidoxime chloride</name>
<activeMoiety>
<activeMoiety>
<name>pralidoxime</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>pralidoxime chloride</name>
</genericMedicine>
</asEntityWithGeneric>
<asContent>
<quantity>
<numerator unit="mL" value="20">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="20" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="60977-141-27" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL" />
<asContent>
<quantity>
<numerator value="6">
<translation code="C48551" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL" value="6" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="60977-141-01" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX" />
</containerPackagedMedicine>
</asContent>
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-c760c9c2-6a21-4a73-8349-6bfdbeb8f594">
<id root="32C3EFE0-814B-5621-EFA8-E005E6FCA245" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-fe7d716e-0f58-4c3e-a144-f46fb7646473" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-68090954-df92-4251-a500-9f226ae937a9"><paragraph ID="INV-45a2e8e1-2440-48cd-ae84-ecf85fbfac9a">Chemical name:
                            2-formyl-1-methylpyridinium chloride oxime. Available in the United
                            States as PROTOPAM Chloride, pralidoxime chloride is frequently referred
                            to as 2-PAM Chloride.</paragraph><paragraph ID="INV-739274e6-c2d4-4fe1-8b94-08d0bd39dbd5">Structural formula:</paragraph><renderMultiMedia referencedObject="MM-f0329da2-91a0-479d-95a3-542e528559d1"><caption>C<sub>7</sub>H<sub>9</sub>CIN<sub>2</sub>O    M.W.
                            172.61</caption>
</renderMultiMedia><paragraph ID="INV-54d95c41-795e-4f5f-a8a5-f60c76139f78">Pralidoxime
                            chloride occurs as an odorless, white, nonhygroscopic, crystalline
                            powder which is soluble in water. Stable in air, it melts between 215&#186;
                            and 225&#186; C, with decomposition.</paragraph><paragraph ID="INV-6c149067-7c77-4617-be12-afb6b9a81850">The specific
                            activity of the drug resides in the 2-formyl-1-methylpyridinium ion and
                            is independent of the particular salt employed. The chloride is
                            preferred because of physiologic compatibility, excellent water
                            solubility at all temperatures, and high potency per gram, due to its
                            low molecular weight.</paragraph><paragraph ID="INV-217e7ce0-2814-40a8-9cdc-f21ce7c617ea">Pralidoxime
                            chloride is a cholinesterase reactivator.</paragraph><paragraph ID="INV-737486c8-7ee1-40d8-8483-ec1140f7e222">PROTOPAM Chloride
                            for intravenous injection or infusion is prepared by cryodesiccation.
                            Each vial contains 1 g of sterile pralidoxime chloride, and NaOH to
                            adjust pH, to be reconstituted with 20 mL of Sterile Water for
                            Injection, USP. The pH of the reconstituted solution is 3.5 to 4.5.
                            Intramuscular or subcutaneous injection may be used when intravenous
                            injection is not feasible.</paragraph></text>
<effectiveTime value="20060511" />
<component>
<observationMedia ID="MM-f0329da2-91a0-479d-95a3-542e528559d1">
<value mediaType="image/jpeg"><reference value="Protopam-Chloride-for-Injection-Figure001.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="INV-e8461e37-de24-4915-9b4d-6e837cfbfcad">
<id root="EEDEC641-B2C7-6575-7867-B43F060E4870" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-f70a0041-c79a-459c-9c22-1d12c39e1ed3" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text ID="INV-ab62f7be-2c77-426b-bb77-8f068c520665"><paragraph ID="INV-9d0ce5d4-495e-4bbe-a774-48262229ee60">The principal
                            action of pralidoxime is to reactivate cholinesterase (mainly outside of
                            the central nervous system) which has been inactivated by
                            phosphorylation due to an organophosphate pesticide or related compound.
                            The destruction of accumulated acetylcholine can then proceed, and
                            neuromuscular junctions will again function normally. Pralidoxime also
                            slows the process of &#8220;aging&#8221; of phosphorylated cholinesterase to a
                            nonreactivatable form, and detoxifies certain organophosphates by direct
                            chemical reaction. The drug has its most critical effect in relieving
                            paralysis of the muscles of respiration. Because pralidoxime is less
                            effective in relieving depression of the respiratory center, atropine is
                            always required concomitantly to block the effect of accumulated
                            acetylcholine at this site. Pralidoxime relieves muscarinic signs and
                            symptoms, salivation, bronchospasm, etc., but this action is relatively
                            unimportant since atropine is adequate for this purpose.</paragraph><paragraph ID="INV-1b3cffde-55dd-4158-8a91-31ec51b430b0">Pralidoxime is
                            distributed throughout the extracellular water; it is not bound to
                            plasma protein. The drug is rapidly excreted in the urine partly
                            unchanged, and partly as a metabolite produced by the liver.
                            Consequently, pralidoxime is relatively short acting, and repeated doses
                            may be needed, especially where there is any evidence of continuing
                            absorption of the poison.</paragraph><paragraph ID="INV-a1f23afa-bd6a-4393-aa31-a6119a446a96">The minimum
                            therapeutic concentration of pralidoxime in plasma is 4 &#181;g/mL; this
                            level is reached in about 16 minutes after a single injection of 600&#160;mg
                            PROTOPAM Chloride. The apparent half-life of PROTOPAM Chloride is 74 to
                            77&#160;minutes.</paragraph><paragraph ID="INV-ef614823-062f-4770-8c48-0c78761b0e80">It has been
                            reported <linkHtml ID="INV-6b1d42c1-1441-4bc2-9b03-7222075469b5" href="#INV-4d1e7195-1340-4799-86e1-190030a497aa"> [1]</linkHtml>
                            that the supplemental use of oxime cholinesterase reactivators (such as
                            pralidoxime) reduces the incidence and severity of developmental defects
                            in chick embryos exposed to such known teratogens as parathion, bidrin,carbachol, and neostigmine. This protective effect of the oximes was
                            shown to be dose related.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-142ad9b3-9c1f-4710-b6ad-57a45c6fffaf">
<id root="D74A96CB-73A9-79FA-45EB-E824110FD7DF" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-8d7d039e-042f-4e5e-8df7-4e77bf8f6311" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-1fe5a46c-87b5-40d3-9873-1d6bd7cda621"><paragraph ID="INV-2746ce2b-86f6-44c8-a33c-a2d0e7b258ae">PROTOPAM is
                            indicated as an antidote: (1) in the treatment of poisoning due to those
                            pesticides and chemicals of the organophosphate class which have
                            anticholinesterase activity and (2) in the control of overdosage by
                            anticholinesterase drugs used in the treatment of myasthenia gravis.</paragraph><paragraph ID="INV-eac6c9d0-93b5-4dd8-92fc-2d7fe01afcd3">The principal
                            indications for the use of pralidoxime are muscle weakness and
                            respiratory depression. In severe poisoning, respiratory depression may
                            be due to muscle weakness.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-77eae0d4-1687-4d34-a77f-a250329667c2">
<id root="F3038F86-A919-0CC3-393A-543596DE9D6F" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-1681e518-2777-4241-a889-dfb1af494270" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-a7a00c48-76b9-4715-b76f-7723e7b954e1"><paragraph ID="INV-a2c36b36-4d5f-4fb2-87a9-1e5f1c8d44de">There are no known
                            absolute contraindications for the use of PROTOPAM. Relative
                            contraindications include known hypersensitivity to the drug and other
                            situations in which the risk of its use clearly outweighs possible
                            benefit (see <linkHtml ID="INV-e886c8df-0976-408e-b66a-e9881ddb4318" href="#INV-53f58d88-1448-4197-b797-bc444a463101">PRECAUTIONS</linkHtml>).</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-bbe02483-3408-45ab-8ab9-50aaede5fb2b">
<id root="BDE140DD-F3FC-3708-C7B9-B026141B5523" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-53bcd99c-b16f-4595-8e7d-fd3674f651a8" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-3dc07154-080e-4670-b7ac-5962aedacee6"><paragraph ID="INV-64f0f25b-e196-4387-9e30-d8d17d0e4460">PROTOPAM is not
                            effective in the treatment of poisoning due to phosphorus, inorganic
                            phosphates, or organophosphates not having anticholinesterase activity.</paragraph><paragraph ID="INV-c801c7f7-176b-4ed2-948c-21bc9c014129">PROTOPAM is <content styleCode="bold">not</content> indicated as an antidote for
                            intoxication by pesticides of the carbamate class since it may increase
                            the toxicity of carbaryl.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-b99ab8ca-ec40-425e-9e7b-47f35ed96c4e">
<id root="056A7F38-CE90-600F-1BB6-0C7DE07B1792" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title ID="INV-972fcd62-54d9-461e-bbb1-2fbad77192f3" mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<effectiveTime value="20060511" />
<component>
<section ID="INV-7352c562-66e6-472b-8dd4-23eed8e12ea4">
<id root="A49E77E9-C772-876D-E9BB-605C5B7EBEEB" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS SECTION" />
<title ID="INV-37214e35-0ba7-42b6-93fd-79f8eecbe773" mediaType="text/x-hl7-title+xml">General</title>
<text ID="INV-6f7163f4-72e0-483c-91e3-0734c1bcdf51"><paragraph ID="INV-53f58d88-1448-4197-b797-bc444a463101">Pralidoxime
                                    has been very well tolerated in most cases, but it must be
                                    remembered that the desperate condition of the
                                    organophosphate-poisoned patient will generally mask such minor
                                    signs and symptoms as have been noted in normal subjects.</paragraph><paragraph ID="INV-35e81663-639c-4580-b038-edba44fa79d3">Intravenous
                                    administration of PROTOPAM should be carried out slowly and,
                                    preferably, by infusion, since certain side effects, such as
                                    tachycardia, laryngospasm, and muscle rigidity, have been
                                    attributed in a few cases to a too-rapid rate of injection. (See<linkHtml ID="INV-abf531c8-be15-4e5d-b4da-36e431655ae4" href="#INV-8edb2787-580b-4f3e-9645-9e1b50cb9aae">DOSAGE AND
                                        ADMINISTRATION</linkHtml>.)</paragraph><paragraph ID="INV-eec153d1-813d-431e-9629-69a6a9dec65b">PROTOPAM
                                    should be used with great caution in treating organophosphate
                                    overdosage in cases of myasthenia gravis since it may
                                    precipitate a myasthenic crisis.</paragraph><paragraph ID="INV-3f61a86b-2ee2-4e74-8025-3bd2ed4b8a26">Because
                                    pralidoxime is excreted in the urine, a decrease in renal
                                    function will result in increased blood levels of the drug.
                                    Thus, the dosage of pralidoxime should be reduced in the
                                    presence of renal insufficiency.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-b30e8db3-612f-4719-a8fa-107402bc358b">
<id root="9BE02D7F-0489-B6CF-BA0B-CD8AD4C98928" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="LABORATORY TESTS SECTION" />
<title ID="INV-1d23b740-9033-42e6-9ae9-b43e24a4687a" mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
<text ID="INV-c2832124-59d3-40b5-a04a-df2d87af852e"><paragraph ID="INV-c87c4579-b3e6-4cb9-8162-0ad61e0a25eb">Treatment
                                    of organophosphate poisoning should be instituted without
                                    waiting for the results of laboratory tests. Red blood cell,
                                    plasma cholinesterase, and urinary paranitrophenol measurements
                                    (in the case of parathion exposure) may be helpful in confirming
                                    the diagnosis and following the course of the illness. A
                                    reduction in red blood cell cholinesterase concentration to
                                    below 50% of normal has been seen only with organophosphate
                                    ester poisoning.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-24b96ee7-aa0f-44c8-9f01-16b54b59ec06">
<id root="136609E0-288C-B382-13D8-B4BB45E2AF27" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG INTERACTIONS SECTION" />
<title ID="INV-5c9884ce-f50a-4266-af6d-1cc40201f867" mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<text ID="INV-aba42e9c-418c-433e-b450-fac94610d712"><paragraph ID="INV-c5c430d4-cb68-4f84-9f17-733258856f6b">When
                                    atropine and pralidoxime are used together, the signs of
                                    atropinization (flushing, mydriasis, tachycardia, dryness of the
                                    mouth and nose) may occur earlier than might be expected when
                                    atropine is used alone. This is especially true if the total
                                    dose of atropine has been large and the administration of
                                    pralidoxime has been delayed. <linkHtml ID="INV-44e4edc4-4864-4061-bafb-203c975dbfcf" href="#INV-4d1e7195-1340-4799-86e1-190030a497aa"> [2-4]</linkHtml></paragraph><paragraph ID="INV-306dc014-3874-4599-a22e-be416926bdb4">The
                                    following precautions should be kept in mind in the treatment of
                                    anticholinesterase poisoning, although they do not bear directly
                                    on the use of pralidoxime: since barbiturates are potentiated by
                                    the anticholinesterases, they should be used cautiously in the
                                    treatment of convulsions; morphine, theophylline, aminophylline,
                                    succinylcholine, reserpine, and phenothiazine-type tranquilizers
                                    should be avoided in patients with organophosphate
                                poisoning.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-31a2e97c-6a75-4e92-a6d9-f1086b16a938">
<id root="C1EDA9B9-BEB2-D0DE-E61B-E9F532E4ACD4" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY SECTION" />
<title ID="INV-dbd21823-46c1-4e0c-a534-690449ddabbb" mediaType="text/x-hl7-title+xml">Carcinogenesis,                 Mutagenesis, Impairment of Fertility</title>
<text ID="INV-af695959-0c73-4532-85b6-0d6c9ee9da20"><paragraph ID="INV-4b51415b-843c-4157-87c4-18c24241211a">Since
                                    pralidoxime chloride is indicated for short-term emergency use
                                    only, no investigations of its potential for carcinogenesis,
                                    mutagenesis, or impairment of fertility have been conducted by
                                    the manufacturer, or reported in the literature.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-c06773a0-f9b7-4284-a0b8-c61526bed794">
<id root="1A980CBE-E782-8737-C4AC-381615851EC1" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-b7603065-2a06-4f7d-8ea9-69c4ec92998f" mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060511" />
<component>
<section ID="INV-e118b769-528f-49d2-91ce-5f9b3a6a5b2d">
<id root="E89E39C5-FE36-065B-D73B-0E7CAB93505C" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title ID="INV-11255214-ddf4-4dbe-abc7-579a56187f8b" mediaType="text/x-hl7-title+xml">Teratogenic
                                        Effects&#8212;Pregnancy Category C</title>
<text ID="INV-0068aba2-cb9c-4343-bb8d-590ce9a6e491"><paragraph ID="INV-5e895341-ee39-4439-b458-47430113d288">Animal reproduction studies have not been conducted
                                            with pralidoxime. It is also not known whether
                                            pralidoxime can cause fetal harm when administered to a
                                            pregnant woman or can affect reproduction capacity.
                                            Pralidoxime should be given to a pregnant woman only if
                                            clearly needed.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-fd73e142-41a8-4251-942a-c637b9a55f13">
<id root="DF5D39D4-B5C0-2764-CF93-A3D22386405E" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title ID="INV-c814e253-144c-4474-9a0b-75f6453cfb3b" mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text ID="INV-78a832ef-31f3-4a6c-81a4-feb2691aa511"><paragraph ID="INV-afeb9753-f315-4f0f-bccb-3a1f3fa01fa9">It is not
                                    known whether this drug is excreted in human milk. Because many
                                    drugs are excreted in human milk, caution should be exercised
                                    when pralidoxime is administered to a nursing woman.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-15b216f0-2cfb-46bb-b8c3-413ed5b10f1c">
<id root="9CF4034C-C769-CA62-EFF1-9E90828C2E27" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-64a1acd6-b5bd-4ba2-b476-069f34c8c26b" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text ID="INV-6c6b3dd8-6bbf-4a7c-bf13-08f95d9dcf80"><paragraph ID="INV-0b6ab680-881f-4d15-8083-f96ac1191670">Safety and
                                    effectiveness in pediatric patients have not been
                                established.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-722b5f5e-a149-49d1-a550-49ab93f83ecc">
<id root="72207E5F-FF8B-A610-76E9-26F672DE0EE6" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION" />
<title ID="INV-a05ebea1-eccf-4b66-89b6-f1f2c6ad2494" mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text ID="INV-24156766-097d-416c-af9e-de78c358a1b5"><paragraph ID="INV-2ee3d038-f463-4858-b98b-cd8cdda8537c">Clinical
                                    studies of PROTOPAM did not include sufficient numbers of
                                    subjects aged 65 and over to determine whether they respond
                                    differently from younger subjects. Other reported clinical
                                    experience has not identified differences in responses between
                                    the elderly and younger patients. In general, dose selection for
                                    an elderly patient should be cautious, usually starting at the
                                    low end of the dosing range, reflecting the greater frequency of
                                    decreased hepatic, renal, or cardiac function, and of
                                    concomitant or other drug therapy.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-90a7fa57-b82a-4302-8295-24fea7712862">
<id root="8B38F969-DC0F-6F83-363B-E15D19563799" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-fd21e7fc-2e76-4c3b-b1a1-d24ed08820c9" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text ID="INV-60efb359-1e78-4f92-aa8a-ef942b5eab33"><paragraph ID="INV-461e72e6-0671-4d6b-b6ce-a86a8df71339">Forty to 60 minutes
                            after intramuscular injection, mild to moderate pain may be experienced
                            at the site of injection.</paragraph><paragraph ID="INV-c1415fea-03b0-436b-b138-0adeb89e2e9f">Pralidoxime may
                            cause blurred vision, diplopia and impaired accommodation, dizziness,
                            headache, drowsiness, nausea, tachycardia, increased systolic and
                            diastolic blood pressure, hyperventilation, and muscular weakness when
                            given parenterally to normal volunteers who have not been exposed to
                            anticholinesterase poisons. In patients, it is very difficult to
                            differentiate the toxic effects produced by atropine or the
                            organophosphate compounds from those of the drug.</paragraph><paragraph ID="INV-73966211-648b-40b0-abca-0906b610076b">Elevations in SGOT
                            and/or SGPT enzyme levels were observed in 1 of 6 normal volunteers
                            given 1200 mg of pralidoxime chloride intramuscularly, and in 4 of 6
                            volunteers given 1800&#160;mg intramuscularly. Levels returned to normal in
                            about 2 weeks. Transient elevations in creatine phosphokinase were
                            observed in all normal volunteers given the drug. A single intramuscular
                            injection of 330&#160;mg in 1&#160;mL in rabbits caused myonecrosis, inflammation,
                            and hemorrhage.</paragraph><paragraph ID="INV-a69e3056-f336-41c4-9d61-ea41e2c57f77">When atropine and
                            pralidoxime are used together, the signs of atropinization may occur
                            earlier than might be expected when atropine is used alone. This is
                            especially true if the total dose of atropine has been large and the
                            administration of pralidoxime has been delayed. <linkHtml ID="INV-1fb8dca3-fef8-411a-b74c-8927b49996c2" href="#INV-4d1e7195-1340-4799-86e1-190030a497aa"> [2-4]</linkHtml>
                            Excitement and manic behavior immediately following recovery of
                            consciousness have been reported in several cases. However, similar
                            behavior has occurred in cases of organophosphate poisoning that were
                            not treated with pralidoxime. <linkHtml ID="INV-370a8667-8bd7-4195-9c96-eb2190d4b7f2" href="#INV-4d1e7195-1340-4799-86e1-190030a497aa"> [3,5,6]</linkHtml></paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-5ea53653-3240-4028-bef4-b9035b10e273">
<id root="AB8E9D1C-A824-24E1-E488-17B0E5467848" />
<code code="42227-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG ABUSE AND DEPENDENCE SECTION" />
<title ID="INV-9dae324e-de62-4e20-9a60-b3a322d7fffd" mediaType="text/x-hl7-title+xml">DRUG ABUSE AND DEPENDENCE</title>
<text ID="INV-8ae5f42e-2f7f-4a95-9ebb-32ffb4702558"><paragraph ID="INV-766ba615-7b8c-482e-bea3-2974cd515c87">Pralidoxime
                            chloride is not subject to abuse and possesses no known potential for
                            dependence.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-a6efdf98-3684-4526-b84e-2a3e45cb1887">
<id root="619D7EF0-78BD-13A7-EC15-68F8BD329C3A" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE SECTION" />
<title ID="INV-b2e90f5f-8721-410a-b1b4-a89b1e27487b" mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<effectiveTime value="20060511" />
<component>
<section ID="INV-28752fd8-76f1-4266-a387-4b33746067a3">
<id root="8BE2D69C-470F-4B12-FC21-81B6F8FE0DA8" />
<title ID="INV-bf883be5-c875-4a7c-b73f-39d303e69ace" mediaType="text/x-hl7-title+xml">Manifestations of
                                Overdosage</title>
<text ID="INV-f0b25b7f-d678-41f3-86f4-d8e8207cfa57"><paragraph ID="INV-f2386ff2-c991-432d-aafa-ef6571a78c31">Observed in
                                    normal subjects only: dizziness, blurred vision, diplopia,         headache, impaired accommodation, nausea, slight tachycardia. In
                                    therapy it has been difficult to differentiate side effects due
                                    to the drug from those due to the effects of the
                                poison.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-155a401f-d3b6-4d6f-9850-79cf22705a7a">
<id root="FAA0FAA8-F5FB-BB9F-F245-C5F6B3CF963A" />
<title ID="INV-b7f3e708-8fe8-4b15-a415-49e7862369b6" mediaType="text/x-hl7-title+xml">Treatment of
                                Overdosage</title>
<text ID="INV-0dd2ab7f-64a9-4e06-b88e-b5031281fcd9"><paragraph ID="INV-eba4058a-3165-4a7e-afe0-3bc974ce1842">Artificial
                                    respiration and other supportive therapy should be administered
                                    as needed.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-22c5b4b6-3525-48ac-aca0-0fe7df95f5d6">
<id root="F2A2439B-AC5E-289C-051D-393D19719870" />
<title ID="INV-0f71011f-d7f7-45ab-bc74-1415fe6df9fd" mediaType="text/x-hl7-title+xml">Acute Toxicity</title>
<text ID="INV-9e5057b9-dd14-461c-bf05-e5ff4638f5c8"><paragraph ID="INV-0b675b58-9385-4a94-8030-af767f5c848e">IV &#8212; man
                                    TDLo: 14 mg/kg (toxic effects: CNS)</paragraph><paragraph ID="INV-3ddbcd82-685d-4482-8197-c33c3eba9c1e">IV &#8212; rat
                                        LD<sub>50</sub>: 96 mg/kg</paragraph><paragraph ID="INV-cfa3d14a-3e6a-4808-a97a-9167c56523ee">IM &#8212; rat
                                        LD<sub>50</sub>: 150 mg/kg</paragraph><paragraph ID="INV-57bbad90-433c-4e31-a7e9-e70fda08d12c">ORAL &#8212;
                                    mouse LD<sub>50</sub>: 4100 mg/kg</paragraph><paragraph ID="INV-c5c34830-f940-4200-91f7-7462bfde1490">IP &#8212; mouse
                                        LD<sub>50</sub>: 155 mg/kg</paragraph><paragraph ID="INV-26d2b77c-2c9c-4047-afd2-5a094cf541dd">IV &#8212; mouse
                                        LD<sub>50</sub>: 90 mg/kg</paragraph><paragraph ID="INV-26d60d82-e216-4162-adda-e2d13794c707">IM &#8212; mouse
                                        LD<sub>50</sub>: 180 mg/kg</paragraph><paragraph ID="INV-e30c27e8-2da8-4689-8a9f-5899c879986d">IV &#8212; rabbit
                                        LD<sub>50</sub>: 95 mg/kg</paragraph><paragraph ID="INV-1f0a2580-4bec-4b3f-adce-d6b72491f576">IM &#8212; guinea
                                    pig LD<sub>50</sub>: 168 mg/kg</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-58d23d20-f1f2-4f6f-bb9c-e7da2156fd3c">
<id root="0E52218E-5401-0E54-4559-DA72A6E76543" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-e59e2410-ef50-43ea-b6fd-99d516717290" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<effectiveTime value="20060511" />
<component>
<section ID="INV-5a975309-8801-4bda-b801-097a6646d8fd">
<id root="A62664E6-7385-E742-0B9D-B355C284E6F3" />
<title ID="INV-5fc48752-a079-40f5-878b-2c8badcac39f" mediaType="text/x-hl7-title+xml">Organophosphate
                                Poisoning</title>
<text ID="INV-a05cc666-ef98-4b51-b523-43d323cb0257"><paragraph ID="INV-8edb2787-580b-4f3e-9645-9e1b50cb9aae">&#8220;Pralidoxime is most effective if administered immediately
                                    after poisoning. Generally, little is accomplished if the drug
                                    is given more than 36 hours after termination of exposure. When
                                    the poison has been ingested, however, exposure may continue for              some time due to slow absorption from the lower bowel, and fatal
                                    relapses have been reported after initial improvement. Continued
                                    administration for several days may be useful in such patients.
                                    Close supervision of the patient is indicated for at least 48 to
                                    72 hours. If dermal exposure has occurred, clothing should be
                                    removed and the hair and skin washed thoroughly with sodium
                                    bicarbonate or alcohol as soon as possible. Diazepam may be
                                    given cautiously if convulsions are not controlled by atropine.&#8221;<linkHtml ID="INV-a7be30d7-6620-47c4-8043-53c4a73e9aa4" href="#INV-4d1e7195-1340-4799-86e1-190030a497aa"> [7]</linkHtml></paragraph><paragraph ID="INV-c8f01d4d-549d-4fc3-a485-198476bbdf7a">Severe
                                    poisoning (coma, cyanosis, respiratory depression) requires
                                    intensive management. This includes the removal of secretions,
                                    airway management, the correction of acidosis, and hypoxemia.
                                    Atropine should be given as soon as possible after hypoxemia is
                                    improved. Atropine should not be given in the presence of
                                    significant hypoxia due to the risk of atropine-induced
                                    ventricular fibrillation. In adults, atropine may be given
                                    intravenously in doses of 2 to 4 mg. This should be repeated at
                                    5 to 10-minute intervals until full atropinization (secretions
                                    are inhibited) or signs of atropine toxicity appear (delirium,
                                    hyperthermia, muscle twitching).</paragraph><paragraph ID="INV-604dbb1b-8b32-40d5-aecd-4dd9da3e2cd0">Some degree
                                    of atropinization should be maintained for at least 48 hours,
                                    and until any depressed blood cholinesterase activity is
                                    reversed.</paragraph><paragraph ID="INV-04c226b5-ca49-4849-9d60-78f39c63b231">Morphine,
                                    theophylline, aminophylline, and succinylcholine are
                                    contraindicated. Tranquilizers of the reserpine or phenothiazine
                                    type are to be avoided.</paragraph><paragraph ID="INV-d2b7de72-a9c3-48a6-a2b2-7e3155d58699"><content styleCode="italics">After</content> the effects of atropine
                                    become apparent, PROTOPAM (pralidoxime chloride) may be
                                    administered.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-bd289849-a443-455a-9fd2-911502f84b96">
<id root="F64EC664-AD7B-FD65-B5E3-EDCBBEDBA07F" />
<title ID="INV-26587daf-2181-4cb0-84c6-8277724fbc0c" mediaType="text/x-hl7-title+xml">PROTOPAM Chloride
                                Injection</title>
<text ID="INV-d21f9bde-57c6-4aa4-9344-095edc165b8a"><paragraph ID="INV-b22b4970-03bb-4f91-8412-294f53f38c0f">Parenteral
                                    drug products should be inspected visually for particulate
                                    matter and discoloration prior to administration, whenever
                                    solution and container permit.</paragraph><paragraph ID="INV-20f00cff-e39d-458e-8f94-bd34815d47f6">Discard
                                    unused solution after a dose has been withdrawn.</paragraph><paragraph ID="INV-3ed8ac02-5db5-4563-87ff-83bdf9eddfbd"><content styleCode="italics">In adults</content>, inject an initial
                                    dose of 1 to 2 g of PROTOPAM, preferably as an infusion in 100
                                    mL of saline, over a 15- to 30-minute period. If this is not
                                    practical or if pulmonary edema is present, the dose should be
                                    given slowly by intravenous injection as a 5 percent solution in
                                    water over not less than five minutes. After about an hour, a
                                    second dose of 1 to 2 g will be indicated if muscle weakness has
                                    not been relieved. Additional doses may be given cautiously if
                                    muscle weakness persists.</paragraph><paragraph ID="INV-7f35ec26-e3e6-44cc-a9fc-e12b99d9b96c">Too-rapid
                                    administration may result in temporary worsening of cholinergic
                                    manifestations. Injection rate should not exceed 200 mg/minute.
                                    If intravenous administration is not feasible, intramuscular or
                                    subcutaneous injection should be used.</paragraph><paragraph ID="INV-e1d803ff-72fe-47ae-96db-d7ef2be3e54a">In severe
                                    cases, especially after ingestion of the poison, it may be
                                    desirable to monitor the effect of therapy
                                    electrocardiographically because of the possibility of heart
                                    block due to the anticholinesterase. Where the poison has been
                                    ingested, it is particularly important to take into account the
                                    likelihood of continuing absorption from the lower bowel since
                                    this constitutes new exposure. In such cases, additional doses           of PROTOPAM (pralidoxime) may be needed every three to eight
                                    hours. In effect, the patient should be &#8220;titrated&#8221; with PROTOPAM
                                    as long as signs of poisoning recur. As in all cases of
                                    organophosphate poisoning, care should be taken to keep the
                                    patient under observation for at least 24 hours.</paragraph><paragraph ID="INV-188c6139-41eb-4917-b663-5e875d968bfd">If                                  convulsions interfere with respiration, they may be controlled
                                    by the slow intravenous injection of diazepam, up to 20 mg in
                                    adults.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-c9dfc0c5-7215-4355-a41c-19a72b0e7c5b">
<id root="45580F15-5EE3-51C3-0D72-30BE0230349D" />
<title ID="INV-db65ae9e-3307-40e7-8659-41056a3261a4" mediaType="text/x-hl7-title+xml">Anticholinesterase
                                Overdosage</title>
<text ID="INV-ce25a65b-d68b-489b-aa8d-1fb3162706e8"><paragraph ID="INV-d996e421-8163-4a2d-b070-960a9e666070">As an
                                    antagonist to such anticholinesterases as neostigmine,
                                    pyridostigmine, and ambenonium, which are used in the treatment
                                    of myasthenia gravis, PROTOPAM may be given in a dosage of 1 to
                                    2 g intravenously followed by increments of 250 mg every five
                                    minutes.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-0ac981e5-d66e-4328-a53e-5534c7061ba1">
<id root="3F21A397-0C82-D5C1-7064-4BA3A147A23F" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-30a44e8b-8f9c-4eaf-b5bf-ff5ddd1cdb39" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-43e8a5f7-666c-4e4a-a7d7-4cb4e3c9b5da"><paragraph ID="INV-f5b7dd25-29f9-4ab5-b0cb-0764b0666d60">NDC
                                60977-141-01&#8212;<content styleCode="italics">Hospital
                            Package:</content> This contains six 20 mL vials of 1 g each of sterile
                            PROTOPAM Chloride (pralidoxime chloride) white to off-white porous
                            cake*, without diluent or syringe. Solution may be prepared by adding 20
                            mL of Sterile Water for Injection, USP. These are single-dose vials for
                            intravenous injection or for intravenous infusion after further dilution
                            with physiologic saline. Intramuscular or subcutaneous injection may be
                            used when intravenous injection is not feasible.<br /><br /></paragraph><table><col align="left" width="500pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">*When necessary, sodium
                                        hydroxide is added during processing to adjust the pH.</td></tr>
</tbody>
</table></text>
<effectiveTime value="20060511" />
<component>
<section ID="INV-87b3178d-334e-4a90-b7a4-7f675e7c8896">
<id root="6CC50182-CF23-E670-2CB2-214D8B07F449" />
<title ID="INV-36376b3a-5377-4ac1-8442-bbc908f1fe6c" mediaType="text/x-hl7-title+xml">Storage</title>
<text ID="INV-6e47ae74-b2b9-4fd1-a854-48e21e85d048"><paragraph ID="INV-d7e7a2a3-c7a7-4fd8-a568-109bf21d47b8"><content styleCode="bold">Store at 20&#176;-25&#176;C (68&#176;-77&#176;F),
                                        excursions permitted to 15&#176;-30&#176;C (59&#176;-86&#176;F) [see USP       Controlled Room Temperature]. </content></paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-67271d75-dda5-4d77-9e5e-1f941d6bbd51">
<id root="4B60CB5F-8251-4919-2FB7-F04EDDA0971B" />
<code code="34091-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ANIMAL PHARMACOLOGY AND OR TOXICOLOGY SECTION" />
<title ID="INV-e3a41648-d926-4ae1-a82f-1b320d35f82c" mediaType="text/x-hl7-title+xml">ANIMAL PHARMACOLOGY AND
                        TOXICOLOGY</title>
<text ID="INV-72393bf3-7ba5-4b49-b0df-91a3c6cc0a9f"><paragraph ID="INV-73bc1e43-1158-48ab-98c3-926567076e77">The following table
                            lists chemical and trade or generic names of pesticides, chemicals, and
                            drugs against which PROTOPAM (usually administered in conjunction with
                            atropine) has been found to have antidotal activity on the basis of
                            animal experiments. All compounds listed are organophosphates having
                            anticholinesterase activity. A great many additional substances are in
                            industrial use but have been omitted because of lack of specific
                            information. <br /><br /></paragraph><table><col align="left" width="600pt" />
<tbody valign="top">
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">AAT&#8212;see
                                        PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">AFLIX<sup>&#174;</sup>&#8212;see FORMOTHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">ALKRON<sup>&#174;</sup>&#8212;see PARATHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">AMERICAN                                      CYANAMID 3422&#8212;see PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">AMITON&#8212;diethyl-S-(2-diethylaminoethyl)phosphorothiolate</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">ANTHIO<sup>&#174;</sup>&#8212;see FORMOTHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">APHAMITE&#8212;see PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">ARMIN&#8212;ethyl-4-nitrophenylethylphosphonate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">AZINPHOS-METHYL&#8212;dimethyl-S-[(4-oxo-1,2,3,-benzotriazin-3(4
                                        H)-yl)methyl] phosphorodithioate</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">MORPHOTHION&#8212;dimethyl-S-2-keto-2-(N-morpholyl)ethylphosphorodithioate</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">NEGUVON<sup>&#174;</sup>&#8212;see TRICHLOROFON</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">NIRAN<sup>&#174;</sup>&#8212;see PARATHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">NITROSTIGMINE&#8212;see PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">O,O-DIETHYL-O-p-NITROPHENYL PHOSPHOROTHIOATE&#8212;see PARATHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">O,O-DIETHYL-O-p-NITROPHENYLTHIO PHOSPHATE&#8212;see PARATHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">OR
                                        1191&#8212;see PHOSPHAMIDON </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">OS
                                        1836&#8212;see VINYLPHOS </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">OXYDEMETONMETHYL&#8212;dimethyl-S-2-(ethylsulfinyl) ethyl
                                        phosphorothiolate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PARAOXON&#8212;diethyl (4-nitrophenyl) phosphate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PARATHION&#8212;diethyl (4-nitrophenyl) phosphorothionate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PENPHOS&#8212;see PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PHENCAPTON&#8212;diethyl-S-(2,5-dichlorophenylmercaptomethyl)
                                        phosphorodithioate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PHOSDRIN<sup>&#174;</sup>&#8212;see MEVINPHOS</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PHOS-KIL&#8212;see PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PHOSPHAMIDON&#8212;1-chloro-1-diethylcarbamoyl-1-propen-2-yl-dimethylphosphate</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PHOSPHOLINE IODIDE<sup>&#174;</sup>&#8212;see echothiophate
                                    iodide</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PHOSPHOROTHIOIC ACID, O,O-DIETHYL-O-p-NITROPHENYL ESTER&#8212;see
                                        PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">PLANTHION&#8212;see PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">QUELETOX&#8212;see FENTHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">RHODIATOX<sup>&#174;</sup>&#8212;see PARATHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">RUELENE<sup>&#174;</sup>&#8212;4-tert-butyl-2-chlorophenylmethyl-N-methylphosphoroamidate</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">SARIN&#8212;isopropyl-methylphosphonofluoridate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">SHELL OS
                                        1836&#8212;see VINYLPHOS </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">SHELL
                                        2046&#8212;see MEVINPHOS </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">SNP&#8212;see
                                        PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">SOMAN&#8212;pinacolyl-methylphosphonofluoridate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">SYSTOX<sup>&#174;</sup>&#8212;diethyl-(2-ethylmercaptoethyl)
                                        phosphorothionate</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">TEP&#8212;see
                                        TEPP </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">TEPP&#8212;tetraethylpyro phosphate </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">THIOPHOS<sup>&#174;</sup>&#8212;see PARATHION</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">TIGUVON&#8212;see FENTHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">TRICHLOROFON&#8212;dimethyl-1-hydroxy-2,2,2-trichloroethylphosphonate</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">VAPONA<sup>&#174;</sup>&#8212;see DICHLORVOS</td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">VAPOPHOS&#8212;see PARATHION </td></tr>
<tr valign="top"><td align="left" styleCode="Botrule " valign="middle">VINYLPHOS&#8212;diethyl-2-chloro-vinylphosphate </td></tr>
</tbody>
</table><paragraph ID="INV-1499435f-5bae-4225-b93e-9aaef5005872"><br />PROTOPAM
                            (pralidoxime chloride) appears to be ineffective, or marginally
                            effective, against poisoning by:</paragraph><list listType="unordered" styleCode="Disc"><item>CIODRIN<sup>&#174;</sup>
                                (alpha-methylbenzyl-3-[dimethoxyphosphinyloxy]-ciscrotonate)</item><item>DIMEFOX (tetramethylphosphorodiamidic fluoride)</item><item>DIMETHOATE
                                (dimethyl-S-[N-methylcarbamoylmethyl]phosphorodithioate)</item><item>METHYL DIAZINON
                                (dimethyl-[2-isopropyl-4-methylpyrimidyl]-phosphorothionate)</item><item>METHYL PHENCAPTON
                                (dimethyl-S-[2,5-dichlorophenylmercaptomethyl]phosphorodithioate)</item><item>PHORATE (diethyl-S-ethylmercaptomethylphosphorodithioate)</item><item>SCHRADAN (octamethylpyrophosphoramide)</item><item>WEPSYN<sup>&#174;</sup> (5-amino-1-[bis-(dimethylamino)
                                phosphinyl]-3-phenyl-1,2,4-triazole).</item></list><paragraph ID="INV-1a79f957-af88-4d23-b5e1-1e5e1915b29c">The use of PROTOPAM
                            should, nevertheless, be considered in any life-threatening situation
                            resulting from poisoning by these compounds, since the limited and
                            arbitrary conditions of pharmacologic screening do not always accurately                 reflect the usefulness of PROTOPAM in the clinical
                        situation.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-cb0a5bf1-a180-47f9-8d64-d34cce6be2af">
<id root="E7F1F35F-E66F-019A-5EB0-C76AA6F2E143" />
<code code="34092-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL STUDIES SECTION" />
<title ID="INV-b0a9f0eb-f656-46a9-bdaf-fd6d63e5d119" mediaType="text/x-hl7-title+xml">CLINICAL STUDIES</title>
<text ID="INV-b4db8fc3-1308-4979-a435-8104c2d698f1"><paragraph ID="INV-750c00f8-4afa-45c6-a39e-b13d3283dbf3">The use of PROTOPAM
                            (pralidoxime) has been reported in the treatment of human cases of
                            poisoning by the following substances:</paragraph><list listType="unordered" styleCode="Disc"><item>Azodrin</item><item>Diazinon</item><item>Dichlorvos (DDVP) with chlordane</item><item>Disulfoton</item><item>EPN</item><item>Isoflurophate</item><item>Malathion</item><item>Metasystox I<sup>&#174;</sup> and Fenthion</item><item>Methyldemeton</item><item>Methylparathion</item><item>Mevinphos</item><item>Parathion</item><item>Parathion and Mevinphos</item><item>Phosphamidon</item><item>Sarin</item><item>Systox<sup>&#174;</sup></item><item>TEPP</item></list><paragraph ID="INV-a25501da-13a6-471b-a896-0b158cf3c367">Of these cases,
                            over 100 were due to parathion, about a dozen each to malathion,
                            diazinon, and mevinphos, and a few to each of the other
                        compounds.</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
<component>
<section ID="INV-bde36d40-a9d1-4bf6-991d-5ee64d5eb48f">
<id root="2A3F0F87-86B3-C81A-9607-2A6AEA87CD61" />
<code code="34093-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="REFERENCES SECTION" />
<title ID="INV-eb54b60d-8dea-4c1d-aa8b-75ff7f6629b7" mediaType="text/x-hl7-title+xml">REFERENCES</title>
<text ID="INV-495e5d8b-dbd3-44ec-9c10-a4e3cfa56a01"><list listType="ordered" styleCode="Arabic"><item>LANDAUER, W.: Cholinomimetic teratogens. V. The effect of oximes
                                and related cholinesterase reactivators, Teratology 15:33 (Feb)
                                1977.</item><item>MOLLER, K.O., JENSEN-HOLM, J., and LAUSEN, H.H.: Ugeskr. Laeg.
                                123:501, 1961.</item><item>NAMBA, T., NOLTE, C.T., JACKREL, J. and GROB, D.: Poisoning due to
                                organophosphate insecticides. Acute and chronic manifestations,
                                Amer. J. Med. 50:475 (Apr), 1971.</item><item>ARENA, J.M.: Poisoning, Toxicology Symptoms, Treatments, ed. 4,
                                Springfield, IL, Charles C. Thomas, 1979, p. 133.</item><item>BRACHFELD, J., and ZAVON, M.R.: Organic phosphate (Phosdrin&#174;)
                                intoxication. Report of a case and the results of treatment with              2-PAM, Arch. Environ. Health 11:859, 1965.</item><item>HAYES, W.J., Jr.: Toxicology of Pesticides, Baltimore, The                                Williams &amp; Wilkins Company, 1975, p. 416.</item><item>AMA Department of Drugs: AMA Drug Evaluations, ed. 4, Chicago,
                                American Medical Association, 1980, p. 1455.</item></list><paragraph ID="INV-4d1e7195-1340-4799-86e1-190030a497aa">Baxter and Protopam
                            are trademarks of Baxter International, Inc., or its subsidiaries.</paragraph><paragraph ID="INV-359ca6fe-d238-47b5-ae4e-16d965fc323a">Manufactured for</paragraph><paragraph ID="INV-2415b0d5-cd0e-4a75-8b93-2ca72f35d436"><content styleCode="bold">Baxter Healthcare Corporation</content></paragraph><paragraph ID="INV-e6b34903-39df-414e-8754-c8988ba1a276">Deerfield, IL 60015
                            USA</paragraph><paragraph ID="INV-19ca5a3f-4098-4cf1-92b6-9ddc3b7e2567">By: Baxter
                            Pharmaceutical Solutions LLC</paragraph><paragraph ID="INV-be326b0d-fe77-4efb-9373-5bf6b685fa4f">Bloomington, IN
                            47403</paragraph><paragraph ID="INV-cf5db48f-f555-4c1e-bd20-3d1dfcea16f2">For Product Inquiry
                            1 800 ANA DRUG (1-800-262-3784)</paragraph><paragraph ID="INV-819674c7-95a6-4373-897f-af35793b394a">MLT-18/3.0</paragraph></text>
<effectiveTime value="20060511" />
</section>
</component>
</structuredBody>
</component>
</document>
